Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3(4): 72-85 [DOI: 10.5497/wjp.v3.i4.72]
Corresponding Author of This Article
Fabio Corsi, MD, Professor, Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, via G. B. Grassi, 74, 20157 Milan, Italy. fabio.corsi@unimi.it
Research Domain of This Article
Nanoscience & Nanotechnology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: All authors contributed to this paper.
Correspondence to: Fabio Corsi, MD, Professor, Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, via G. B. Grassi, 74, 20157 Milan, Italy. fabio.corsi@unimi.it
Telephone: +39-2-39043449 Fax: +39-2-50319846
Received: July 28, 2014 Revised: August 29, 2014 Accepted: September 23, 2014 Published online: December 9, 2014
Core Tip
Core tip: About 30% of human breast cancers are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) receptor, which determines the deregulation of cell survival and proliferation pathways. The HER2-targeted therapy is the most effective treatment, despite some related limitations, which could be bypassed with the development of nanoparticles for HER2-targeted drug delivery, photothermal ablation or photodynamic therapy. Here, we describe HER2+ breast cancer features and anti-HER2 therapy, and focus on the contribution of nanomedicine in this context, by reporting HER2-targeted nanoparticles under preclinical investigations. Promising results suggest upcoming clinical application of these nano-compounds in the next future.